The US Food and Drug Administration has launched a unified system for collecting and publishing adverse-event reports across the products it regulates. The Adverse Event Monitoring System, known as AEMS, is intended to replace separate reporting databases and make new reports publicly searchable much sooner.
The agency announced the system on March 11, 2026. Its initial phase includes reports involving drugs, biologics, vaccines, cosmetics and animal food. Other product centers, including those responsible for medical devices, tobacco, human food and veterinary products, are scheduled to move into the platform by the end of May.
That change can improve access to safety signals, but it does not turn every report into a verified side effect. A report records a suspected association submitted by a patient, clinician, manufacturer or another reporter. It does not, by itself, show that a product caused the event.
AEMS Consolidates Seven Legacy Databases
The FDA says it receives about six million adverse-event reports each year through seven databases. AEMS is designed to put those reports into one cross-product platform with a common public dashboard.
The first migration includes the FDA Adverse Event Reporting System for drugs, the Vaccine Adverse Event Reporting System and the Center for Food Safety and Applied Nutrition's adverse-event system. Later migrations are planned for medical-device, human-food, tobacco and veterinary reporting systems.
The agency estimates that replacing the separate systems will save about $120 million over five years, compared with annual costs of roughly $37 million for the legacy databases. Those are agency projections, not measured savings from a completed transition. The old databases, application interfaces and analytics tools will be retired in stages as migration continues.
Real-Time Publication Is Not Real-Time Causation
The FDA had already started publishing new drug and therapeutic-biologic reports daily in August 2025, replacing a quarterly release schedule for that dataset. AEMS is a broader project: it combines reports from different regulated-product categories and is meant to make them searchable through a single interface.
Faster publication can help researchers, clinicians and the public notice clusters that deserve examination. It cannot resolve the questions that determine whether a signal represents a real product risk. Regulators still have to assess timing, medical history, other treatments, biological plausibility, reporting patterns and evidence from clinical or epidemiological studies.
The FDA warns that AEMS data can include incomplete records and duplicate reports. The existence of a report also does not establish how often an event occurs because the database does not provide a reliable count of all people exposed to a product. Raw totals therefore cannot be used to compare the safety of two products or calculate an incidence rate without additional evidence.
The Rollout Continues Through May
The March launch is a phased deployment rather than a finished conversion. The FDA says the remaining product centers will be added by the end of May 2026. Historical data will also be migrated, and legacy systems will be decommissioned as their functions move into AEMS.
One related change begins on April 1, when sponsors of investigational new drug applications must submit specified safety reports electronically through AEMS. That requirement concerns reports generated during drug development and is distinct from the public's ability to browse post-market reports.
Until the migration is complete, users may need to understand which product categories and historical periods are available in the new dashboard. A unified interface is useful only if the underlying coverage, update schedule and reporting limitations remain visible.
Transparency Only Works With Context
AEMS could reduce the delay between a report reaching the FDA and the public seeing it. It may also make cross-product searches easier and reduce the technical burden of maintaining multiple databases. Neither benefit eliminates the need for careful safety investigation.
Public reporting systems are especially vulnerable to misreading after a widely discussed event, when awareness can cause submissions to rise. A higher count can reflect a true problem, increased use of a product, publicity, duplicate filing or some combination of those factors. The dashboard is a starting point for questions, not a scoreboard of proven harm.
The meaningful advance is not that a database can produce alarming numbers faster. It is that regulators and independent researchers can see potential signals sooner and test them against stronger evidence. If speed is separated from context, real-time transparency can accelerate false conclusions as efficiently as it accelerates scrutiny. AEMS will earn trust through complete coverage, clear limitations and disciplined follow-up, not through the raw volume of reports it displays.